Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

Rhea-AI Summary

Biofrontera AG (NASDAQ: BFRA) will announce its financial results for the first nine months ending September 30, 2021, on November 17, 2021. Following this, there will be conference calls for shareholders on November 18, 2021, in German at 10:00 am CET and in English at 2:00 pm CET. The calls can be accessed via designated dial-in numbers. Biofrontera specializes in dermatological drugs, notably the combination of Ameluz and BF-RhodoLED for treating superficial skin cancers, with a presence in the EU and US markets since 2012 and 2016, respectively.

Positive

• Company's lead product, Ameluz, is established in both EU and US markets.
• Biofrontera is the first German founder-led pharmaceutical company with centralized approvals for its in-house developed drug.

Negative

• None.

Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021.

Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times:

In German, November 18, 2021 at 10:00 am CET (4:00 am ET)
Dial-in number Germany: +49 69201744220
Conference code: 35058739#

In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 22567919#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

-End-

Biofrontera AG
Anke zur Mühlen, Investor Relations
ir@biofrontera.com
+49-214-87632-0

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz^®, a topical prescription drug, and medical device BF-RhodoLED^® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz^® has been marketed in the EU since 2012 and in the United States since May 2016. In the EU, the company also sells the dermocosmetics series Belixos^®, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. www.biofrontera.com.

FAQ

When will Biofrontera AG release its financial results for 2021?

Biofrontera AG will release its financial results for the first nine months of 2021 on November 17, 2021.

What are the timings for Biofrontera AG's conference calls?

The conference calls will be on November 18, 2021, at 10:00 am CET in German and at 2:00 pm CET in English.

What is Biofrontera AG known for?

Biofrontera AG specializes in dermatological drugs, with its lead product being Ameluz for photodynamic therapy.

What is the significance of Ameluz in Biofrontera AG's portfolio?

Ameluz is important as it has been marketed in the EU since 2012 and in the US since 2016, indicating its established presence in key markets.